Humacyte Third Quarter 2026 Earnings Conference Call - HUMACYTE INC

Financial Performance:

• SimVest (SynVest) revenue reached $1.0 million in Q3 2026, a 151% sequential increase from Q2 and a 43% year-over-year increase from Q3 2025; revenue for the nine months ended September 30, 2026, was $1.9 million.
• Gross margins remain negative due to significant overhead ($0.8M in Q3, $1.2M YTD) related to unused production capacity; management expects unused capacity charges to persist in Q4 but eliminate upon ramping production in 2027.
• Research and Development (R&D) expenses decreased to $14.1 million in Q3 (down from $17.3 million in prior year period) due to reduced manufacturing runs and program wind-downs; R&D for nine months was $14.1 million (sequential drop of $4M from Q2).
• General and Administrative (G&A) expenses rose to $9.0 million in Q3 primarily due to a $0.6 million non-cash reserve for shareholder litigation settlement.
• Net loss was $15.5 million for Q3 (improved from $17.5 million prior year) but $70.0 million for the nine months (deteriorated from $16.0 million) driven by non-cash remeasurement of contingent earn-out liabilities.
• Cash, cash equivalents, and restricted cash stood at $64.9 million as of September 30, 2026; operating cash use declined to $15.0 million for the quarter and $62.1 million YTD due to cost reduction measures and lower inventory production costs.

Guidance and Future Outlook:

• Q4 2026 sales are projected to at least double Q3 results ($1.0M), driven by October sales of $800,000 and expected addition of at least 20 new hospital orders by year-end.
• Supplemental Biologics License Application (SBLA) for ATEV in dialysis access is scheduled for submission in November; FDA acceptance expected in January.
• Management anticipates a potential Priority Review status; a successful Priority Review could yield a PDUFA date in May 2027 with a commercial launch in June, while standard review would push launch to late 2027.
• The Phase IIa clinical study for CTEV in coronary artery bypass grafting (CABG) is active and screening patients; this is the first in-human study for a new off-the-shelf conduit in this indication in 40 years.
• Full-year 2027 outlook is optimistic, with management predicting robust revenue growth and improved gross margins as production utilization increases and overhead charges from unused capacity cease.

Business Segments and Product Lines:

• SimVest (Vascular Injury): Hospital adoption expanded 44% in Q3, growing from 34 to 49 hospitals; commercial team revamped in H1 2026 to leverage vascular surgery relationships and pricing incentives.
• ATEV (Dialysis Access): SBLA filing supported by three Phase III trials (VO7, VO12, and another); VO12 data showed patients achieved functional access >3 months sooner than AV fistula standard of care.
• CTEV (CABG): First human Phase IIa study initiated; preclinical data and large animal manufacturing batches are complete, targeting an alternative to saphenous vein grafts.
• Biovascular Pancreas: Remains a pipeline project with a publication in press on primate islet survival data; resource allocation deferred until 2027 pending cash flow improvement.
• International Expansion: MAA application filed in Israel for SimVest and under active review; exploring opportunities in the Middle East.

Market and Competitive Landscape:

• Dialysis access market presents a $2–$3 billion Total Addressable Market (TAM) in the US, serving ~500,000 patients entering dialysis annually with potential for ~100,000 new procedures and 20,000 revisions.
• No new off-the-shelf conduits introduced for CABG in the US in four decades; CTEV aims to disrupt the saphenous vein graft market.
• SimVest has penetrated major metropolitan trauma centers and vascular practices, with adoption scaling from emergency use to planned cases as surgeon familiarity grows.
• Competitive advantage cited includes the "first-in-class" biologic nature, ability to save limbs/lives, and strong surgeon education programs facilitating faster adoption cycles.

Risks and Challenges:

• Regulatory Risk: FDA review timeline depends on Priority Review designation; delayed approval could push commercial launch to late 2027.
• Production Capacity: Current low production runs result in high unit costs due to allocated overhead; profitability is contingent on hitting robust 2027 production schedules to absorb fixed costs.
• Reimbursement & Payer Acceptance: Success in dialysis market requires convincing value-based care organizations and CMS of cost-saving benefits; ongoing work involves detailed budget impact models and alignment with Medicare fee-for-service data.
• Litigation: Shareholder litigation settlement reserve ($0.6M) impacted G&A expenses, though no material cash outflow is currently anticipated beyond the reserve.

Management Commentary and Tone:

• CEO Dr. Laura Nicholson described the call as an "inflection point" and expressed high confidence in the company's turnaround, citing a revamped commercial structure and strong product efficacy.
• Chief Commercial Officer Jim Mercadante emphasized the success of the new commercial team, noting that "every patient matters" and highlighting the rapid ramp-up in hospital orders.
• Tone was optimistic and confident, with management projecting a virtuous cycle of better education leading to better outcomes and further adoption.
• Management acknowledged the challenges of the "long and arduous journey" but stressed that commercial execution is now significantly improved compared to previous quarters.

Analyst Questions and Answers:

• Durability of Adoption (Ryan Zimmerman, BTIG): Management confirmed durability stems from hiring leadership with deep vascular surgery relationships, retooling marketing/messaging, and introductory pricing to facilitate initial hospital trials.
• Commercial Readiness for Dialysis (Laura Nicholson/Dale Sander): Confirmation that existing vascular surgeon relationships will accelerate dialysis launch (80% overlap in surgeons) and that reimbursement models are being built with nephrology advisors (Drs. Roy Chowdhury and Kossman).
• Pricing and ASP (Chris Pasquale, Barclays): Average selling price is near the $17,000 list price, though introductory/evaluation pricing in Q3 diluted ASP; ASP is expected to strengthen in future quarters.
• Gross Margin Timing (Chris Pasquale, Barclays): Negative gross margins expected to persist in Q4 due to unused capacity overhead; positive margins expected to return in 2027 as production utilization increases.
• Pipeline Focus (Bruce Jackson, StoneX): Biovascular pancreas progress is ongoing at benchtop level with a publication in press, but strategic focus remains on commercializing SimVest and manufacturing for the next 6 months.
• Real-World Data (Josh Jennings, TD Cowen): Multiple physician case studies are being prepared for presentation at VESS (Vascular Endovascular Society of America) and other forums, highlighting successful off-label and on-label use.

Other Key Points:

• Leadership Changes: Hired Todd Rasmussen as Chief Surgical Officer to lead medical science liaison teams and provide surgeon-to-surgeon education; appointed nephrology advisors for the dialysis pipeline.
• Clinical Data: VO12 Phase III results presented at ASN Kidney Week; VO7 one-year results published in The Lancet Digital Health.
• Manufacturing Success: Achieved 9–10 consecutive successful production lots in late 2025, enabling controlled production runs in 2026 to manage costs.
• Patient Outcomes: VO12 data indicates significant improvement in dialysis catheter-free time and earlier functional access for women compared to standard AV fistula care.